On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera Sciences (Nanjing), Inc., to proceed with its initial public offering (IPO) in Hong Kong.
Proposed Share Issuance and Conversion
TransThera Sciences plans to issue up to 146 million overseas-listed ordinary shares on the Hong Kong Stock Exchange. Additionally, 34 shareholders intend to convert a combined 286,385,673 domestic unlisted shares into overseas-listed shares to be traded on the exchange.
Clinical-Stage Biopharma Focused on Unmet Medical Needs
In June of this year, TransThera Sciences submitted its application to the Hong Kong Stock Exchange. The company’s prospectus reveals that it is a clinical-stage biopharmaceutical company oriented around clinical needs, focusing on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiometabolic diseases. Leveraging its integrated in-house R&D system, TransThera Sciences has established a pipeline of six clinical-stage candidates and one preclinical candidate.
Core Product and Potential Global First-in-Class Drug
The company’s flagship product, Tinengotinib (TT-00420), is a potentially globally first-in-class, registered-stage, self-developed multi-target kinase (“MTK”) inhibitor, primarily targeting three key pathways: FGFR/VEGFR, JAK, and Aurora kinases. Tinengotinib addresses the unmet clinical needs for various recurrent or refractory, drug-resistant solid tumors, including cholangiocarcinoma, prostate cancer, breast cancer, biliary tract cancers (BTC), and pan-FGFR solid tumors.
Commercialization Plans for Tinengotinib in China
TransThera Sciences intends to first commercialize Tinengotinib in China for the treatment of cholangiocarcinoma. Given the typical patient’s search for treatment at hospitals renowned for cholangiocarcinoma care, the company is strategically preparing to establish an internal commercial team due to the accessible target patient population for Tinengotinib.
Fundraising History and Valuation
According to the prospectus, TransThera Sciences has completed nine rounds of financing, with a post-money valuation of 4.59 billion yuan following its latest D+ round of financing.-Fineline Info & Tech
